Amiloride, a diuretic used primarily to treat conditions like hypertension and heart failure, was developed in the mid-20th century and approved for medical use in the late 1960s. Its history is marked by its effectiveness in promoting sodium excretion while conserving potassium, making it useful in combination with other diuretics. Amiloride, a potassium-sparing diuretic that acts on the distal tubules of the kidneys, was approved in the United States in 1967 and is often included in combination therapies to balance electrolyte levels. Its development focused on improving diuretic safety by reducing the risk of hypokalemia, and it has since been widely used in clinical practice for managing fluid balance and blood pressure.
BRAND NAMES
Midamor: Midamor is a prescription medication approved by the U.S. Food and Drug Administration for the treatment of hypertension and edema (fluid retention). Amiloride, the active ingredient in Midamor, is typically used in combination with other diuretics (such as thiazides) to help maintain potassium balance and enhance diuretic effectiveness.
MECHANISM OF ACTION
Amiloride acts as a potassium-sparing diuretic by targeting the distal convoluted tubules and collecting ducts of the kidneys, where it selectively blocks epithelial sodium channels (ENaC) on the luminal membrane of tubular cells. This inhibition reduces sodium reabsorption and decreases the electrochemical gradient that normally drives potassium secretion into the urine, thereby promoting sodium and water excretion while conserving potassium. As a result, amiloride helps lower blood volume and blood pressure and is especially useful in combination with other diuretics to prevent excessive potassium loss and maintain electrolyte balance.
PHARMACOKINETICS
Absorption
bioavailability of about 50%. It can be taken with or without food, as food has minimal effect on its absorption. The drug generally reaches peak plasma concentrations within about 3 to 4 hours after ingestion, allowing it to exert its diuretic effect within a few hours of dosing.
Distribution
Amiloride has a moderate volume of distribution and low plasma protein binding (about 20–30%), which is not significantly affected by drug concentration. It is primarily excreted unchanged by the kidneys, with most of the administered dose eliminated in the urine. The drug has an elimination half-life of approximately 6 to 9 hours, supporting its sustained diuretic effect.
Metabolism
Amiloride undergoes minimal metabolism in the body and is not extensively processed by the liver. A large proportion of the drug is excreted unchanged, primarily through the kidneys. Only a small fraction undergoes minor metabolic transformation before elimination.
Elimination
Amiloride is mainly excreted unchanged by the kidneys, with minimal metabolism, making renal function crucial for its clearance.
PHARMACODYNAMICS
Amiloride acts on the distal convoluted tubules and collecting ducts of the kidneys by blocking epithelial sodium channels (ENaC), reducing sodium reabsorption and conserving potassium. This results in a mild diuretic effect, lowering blood volume and blood pressure. Amiloride’s effects are enhanced when combined with thiazide or loop diuretics, helping prevent potassium loss while promoting sodium and water excretion, and it shows additive benefits in maintaining electrolyte balance in such combination therapies.
ADMINISTRATION
Amiloride is administered orally, usually as tablets. It can be taken with or without food, providing flexibility in dosing. The dosage and frequency depend on the patient’s age, kidney function, and clinical condition. Amiloride is often used in combination with other diuretics, such as thiazides, to enhance fluid removal while preventing potassium loss, and it is important to follow the prescribed schedule consistently to maintain electrolyte balance and therapeutic effect.
DOSAGE AND STRENGTH
Amiloride is typically administered orally, with dosing adjusted based on the patient’s age, kidney function, and clinical condition.
Adults: The usual starting dose is 5–10 mg once or twice daily, with a maximum of 20 mg per day.
Pediatric patients: Dosing is weight-based, generally 0.1–0.2 mg/kg once or twice daily, not exceeding the adult maximum.
Amiloride is often given in combination with other diuretics, such as thiazides, to enhance fluid removal while minimizing potassium loss.
DRUG INTERACTIONS
Amiloride may interact with other potassium-increasing drugs, such as ACE inhibitors or potassium supplements, raising the risk of hyperkalemia, so serum electrolytes should be monitored closely.
FOOD INTERACTIONS
Amiloride has no significant interactions with food and can be taken with or without meals, allowing flexible dosing.
CONTRAINDICATIONS
Amiloride is contraindicated in patients with hyperkalemia, severe kidney impairment, or a known hypersensitivity to amiloride or any of its components.
SIDE EFFECTS
Common side effects of Amiloride include dizziness, headache, nausea, vomiting, and mild gastrointestinal discomfort. It may also cause hyperkalemia, muscle cramps, or fatigue.
In children, less common effects can include mild abdominal pain or electrolyte disturbances.
TOXICITY
The most serious toxicity of Amiloride is hyperkalemia, which can lead to dangerous cardiac arrhythmias if not monitored. High doses or impaired kidney function increase this risk. Rarely, it may also cause dizziness, hypotension, or gastrointestinal disturbances.
